Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Inhibrx, Inc. (INBX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights",
"14 2821 40 100 60 80 20 0 0 7"
05/25/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/08/2023 8-K Quarterly results
Docs: "Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights"
04/26/2023 8-K Quarterly results
03/06/2023 8-K Quarterly results
Docs: "Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results",
"HD 1H 2024 INBRX-109 INBRX-105"
11/16/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
10/26/2022 8-K Quarterly results
10/04/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT",
"80 60 0 40 20",
"Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1study"
08/15/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
04/25/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101"
04/05/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting"
04/04/2022 8-K Investor presentation
Docs: "40 20 0 0 7 14 21 28"
03/03/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
Docs: "Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights"
02/22/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT",
"Inhibrx Announces Amended Loan Agreement with Oxford"
12/01/2021 8-K Other Events  Interactive Data
Docs: "Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma"
11/09/2021 8-K Quarterly results
Docs: "Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights"
10/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors"
10/12/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing",
"VALIDATION FROM INDUSTRY LEADING PARTNERS"
09/03/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
06/08/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
01/13/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy